Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis

Background and Objectives This analysis used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in overweight and obese individuals.